0001213900-22-075598.txt : 20221128 0001213900-22-075598.hdr.sgml : 20221128 20221128182758 ACCESSION NUMBER: 0001213900-22-075598 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221123 FILED AS OF DATE: 20221128 DATE AS OF CHANGE: 20221128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Erfanian Hamid CENTRAL INDEX KEY: 0001893172 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09974 FILM NUMBER: 221427623 MAIL ADDRESS: STREET 1: 527 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENZO BIOCHEM INC CENTRAL INDEX KEY: 0000316253 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 132866202 STATE OF INCORPORATION: NY FISCAL YEAR END: 0731 BUSINESS ADDRESS: STREET 1: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 BUSINESS PHONE: 5167555500 MAIL ADDRESS: STREET 1: ENZO BIOCHEM INC STREET 2: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 4 1 ownership.xml X0306 4 2022-11-23 0 0000316253 ENZO BIOCHEM INC ENZ 0001893172 Erfanian Hamid C/O ENZO BIOCHEM, INC 81 EXECUTIVE BLVD., SUITE 3 FARMINGDALE NY 11735 1 1 0 0 Chief Executive Officer Common Stock, $0.01 Par Value 2022-11-23 4 P 0 100000 1.97 A 374600 D Stock Option (to acquire Common Stock) 1.97 2022-11-23 4 A 0 300000 0 A 2023-11-23 2027-11-23 Common Stock 300000 300000 D Stock Option (to acquire Common Stock) 3.39 2022-11-08 2026-11-08 Common Stock 700000 700000 D The Reporting Person was granted Restricted Stock Units that will vest in three equal installments, beginning on November 23, 2023. The Reporting Person was granted 300,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 23, 2023. The Reporting Person was granted 700,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 8, 2022. /s/ Hamid Erfanian 2022-11-28